Castle Biosciences Inc (CSTL): R&D Expense
$51.85M
Year ended 2025-12-31
$55.45M
Trailing 12 months to 2026-06-30
+4.9%
3-year compound annual growth
+31.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $51.85M | -0.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $52.04M | -2.9% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $53.62M | +19.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $44.90M | +51.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $29.65M | +123.6% | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | $13.26M | +79.5% | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | $7.38M | +52.1% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $4.85M | n/a | 2020-03-10, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $51.85M | -0.4% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $53.91M | +10.4% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $71.43M | -1.5% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $70.81M | +2.2% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $195.79M | -39.3% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $101.58M | -10.8% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $364.19M | +4.7% |
| Biodesix Inc (BDSX) | 2025-12-31 | $12.00M | +25.5% |
Compare CSTL, FLGT, CDNA, BLLN side by side · Screen every company in Services-Medical Laboratories ↗